Home
Clinical Resources Search
PQI: Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

Last Updated: September 2, 2023

By: Houston Holmes, MD

About this PQI

This PQI will discuss the initiation and management of tazemetostat in the treatment of relapsed or refractory (R/R) follicular lymphoma (FL).

More About This PQI

PQI in Action Articles:

Tazemetostat_tazverik_lymphoma pdf 1.85MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Frequently Searched

Supported by

Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

PQI: Datopotamab deruxtecan (DATROWAY): Prophylaxis and Management of Adverse Events

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI in Action: Nirogacestat (Ogsiveo) use in Management of Adults with Progressing Desmoid Tumors (or fibromatosis or aggressive fibromatosis)

PQI in Action: Abiraterone acetate (Yonsa) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

S9 E9: The Realities of Ethics in Oncology

S9 E8: Mental Strength at Work

S9 E7: A Haven of Healing

S9 E6: Healing Through Sound: A Breast Cancer Journey

Readiness Tracker

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Rituximab and Hyaluronidase

PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Epcoritamab

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lenalidomide and Tafasitamab

RICE

ICE

Tazemetostat

PQI in Action: Tazemetostat (Tazverik®)Management in Relapsed/Refractory Follicular Lymphoma

Tazemetostat

PQI in Action: Tazemetostat (Tazverik®)Management in Relapsed/Refractory Follicular Lymphoma

PQI: Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

PQI: Enzalutamide (Xtandi®) In Castration-Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer

Enzalutamide

PQI in Action: Enzalutamide (Xtandi) in Castration Resistant Prostate Cancer or Metastatic Castration-Sensitive Prostate Cancer

Daratumumab and KRd

Overview of BTCEs: Bispecific Antibody Therapy Resource Guide

Taletrectinib

Cobimetinib